Discrimination of clinical stages in non-small cell lung cancer patients by serum HSP27 and HSP70: A multi-institutional case-control study

Clinica Chimica Acta

Volumn 413, Issue 13-14, 2012, Pages 1115-1120

  Zimmermann, Matthias ^a   Nickl, Stefanie ^a   Lambers, Christopher ^a   Hacker, Stefan ^a   Mitterbauer, Andreas ^a   Hoetzenecker, Konrad ^a   Rozsas, Anita ^b   Ostoros, Gyula ^b   Laszlo, Viktoria ^a   Hofbauer, Helmut ^a   Renyi Vamos, Ferenc ^a,c   Klepetko, Walter ^a   Dome, Balazs ^a,b   Ankersmit, Hendrik Jan ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^c NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

Biomarker; Heat shock protein 27; NSCLC

Indexed keywords

HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70;

ADULT; ADVANCED CANCER; ARTICLE; CANCER STAGING; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING;

CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HSP27 HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM STAGING;

EID: 84860377679     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.03.008     Document Type: Article

References (35)

1. Houghton A.M., Mouded M., Shapiro S.D. Common origins of lung cancer and COPD. Nat Med 2008, 14:1023-1024.
2. Kishi K., Gurney J.W., Schroeder D.R., Scanlon P.D., Swensen S.J., Jett J.R. The correlation of emphysema or airway obstruction with the risk of lung cancer: a matched case-controlled study. Eur Respir J 2002, 19:1093-1098.
3. Calabro E., Randi G., La Vecchia C., et al. Lung function predicts lung cancer risk in smokers: a tool for targeting screening programmes. Eur Respir J 2010, 35:146-151.
4. Buist A.S., McBurnie M.A., Vollmer W.M., et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007, 370:741-750.
5. Petty T.L. Are COPD and lung cancer two manifestations of the same disease?. Chest 2005, 128:1895-1897.
6. Brody J.S., Spira A. State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc Am Thorac Soc 2006, 3:535-537.
7. Barnes P.J. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008, 8:183-192.
8. Di Stefano A., Capelli A., Lusuardi M., et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998, 158:1277-1285.
9. Campisi J. Replicative senescence: an old lives' tale?. Cell 1996, 84:497-500.
10. Agusti A.G. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005, 2:367-370. [discussion 71-2].
11. Lambers C., Hacker S., Posch M., et al. T cell senescence and contraction of T cell repertoire diversity in patients with chronic obstructive pulmonary disease. Clin Exp Immunol 2009, 155:466-475.
12. Hacker S., Lambers C., Pollreisz A., et al. Increased soluble serum markers caspase-cleaved cytokeratin-18, histones, and ST2 indicate apoptotic turnover and chronic immune response in COPD. J Clin Lab Anal 2009, 23:372-379.
13. Hacker S., Lambers C., Hoetzenecker K., et al. Elevated HSP27, HSP70 and HSP90 alpha in chronic obstructive pulmonary disease: markers for immune activation and tissue destruction. Clin Lab 2009, 55:31-40.
14. Ankersmit H, Nickl S, Hoeltl E, et al. Increased serum levels of HSP27 as a marker for incipient chronic obstructive pulmonary disease in young smokers. Respiration, [Electronic publication ahead of print March 14, 2012], doi:. http://doi:10.1159/000336557.
15. Wilson D.O., Weissfeld J.L., Balkan A., et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med 2008, 178:738-744.
16. Yang P. Epidemiology of lung cancer prognosis: quantity and quality of life. Methods Mol Biol 2009, 471:469-486.
17. Van't Westeinde S.C., van Klaveren R.J. Screening and early detection of lung cancer. Cancer J 2011, 17:3-10.
18. Aberle D.R., Adams A.M., Berg C.D., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365:395-409.
19. Molina R., Auge J.M., Filella X., et al. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Anticancer Res 2005, 25:1773-1778.
20. Foa P., Fornier M., Miceli R., et al. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res 1999, 19:3613-3618.
21. Rami-Porta R., Crowley J.J., Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009, 15:4-9.
22. Beere H.M. "The stress of dying": the role of heat shock proteins in the regulation of apoptosis. J Cell Sci 2004, 117:2641-2651.
23. van Eden W., van der Zee R., Prakken B. Heat-shock proteins induce T-cell regulation of chronic inflammation. Nat Rev Immunol 2005, 5:318-330.
24. Lebherz-Eichinger D., Ankersmit H.J., Hacker S., et al. HSP27 and HSP70 serum and urine levels in patients suffering from chronic kidney disease. Clin Chim Acta 2012, 413:282-286.
25. Love S., King R.J. A 27 kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer. Br J Cancer 1994, 69:743-748.
26. Kato M., Herz F., Kato S., Hirano A. Expression of stress-response (heat-shock) protein 27 in human brain tumors: an immunohistochemical study. Acta Neuropathol 1992, 83:420-422.
27. Thomas S.A., Brown I.L., Hollins G.W., et al. Detection and distribution of heat shock proteins 27 and 90 in human benign and malignant prostatic tissue. Br J Urol 1996, 77:367-372.
28. Michils A., Redivo M., Zegers de Beyl V., et al. Increased expression of high but not low molecular weight heat shock proteins in resectable lung carcinoma. Lung Cancer 2001, 33:59-67.
29. Huang Q., Zu Y., Fu X., Wu T. Expression of heat shock protein 70 and 27 in non-small cell lung cancer and its clinical significance. J Huazhong Univ Sci Technolog Med Sci 2005, 25:693-695.
30. Malusecka E., Zborek A., Krzyzowska-Gruca S., Krawczyk Z. Expression of heat shock proteins HSP70 and HSP27 in primary non-small cell lung carcinomas. An immunohistochemical study. Anticancer Res 2001, 21:1015-1021.
31. Malusecka E., Krzyzowska-Gruca S., Gawrychowski J., Fiszer-Kierzkowska A., Kolosza Z., Krawczyk Z. Stress proteins HSP27 and HSP70i predict survival in non-small cell lung carcinoma. Anticancer Res 2008, 28:501-506.
32. Volm M., Koomagi R., Mattern J., Stammler G. Heat shock (hsp70) and resistance proteins in non-small cell lung carcinomas. Cancer Lett 1995, 95:195-200.
33. Volm M., Mattern J., Stammler G. Up-regulation of heat shock protein 70 in adenocarcinomas of the lung in smokers. Anticancer Res 1995, 15:2607-2609.
34. Suzuki K., Ito Y., Wakai K., et al. Serum heat shock protein 70 levels and lung cancer risk: a case-control study nested in a large cohort study. Cancer Epidemiol Biomarkers Prev 2006, 15:1733-1737.
35. Wang H., Xing J., Wang F., et al. Expression of Hsp27 and Hsp70 in lymphocytes and plasma in healthy workers and coal miners with lung cancer. J Huazhong Univ Sci Technolog Med Sci 2010, 30:415-420.